Stock listing

BVL:MRNAUS Moderna, Inc. Acciones

Peruvian listing (BVL) of Moderna, Inc. · home listing NASDAQ:MRNA

Follow Moderna, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:MRNA

$195.00 USD -1.79 (-0.9%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:MRNA

Past year +772.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$191.46 – $210.00 USDNov 20, 2026
Volume
9.66M sharesNov 20, 2026
Market cap
$78.90B USDAt the close on Nov 20, 2026 · price × 404.6M shares outstanding
52-week range
$22.28 – $280.80 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.46B USDMedian day 15.44M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Moderna, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MRNA · Home$195.00 USD-1.79 (-0.9%)9,662,576$200.08$210.00$191.46$196.79Close on Nov 20, 2026
Xetra:0QF€182.80 EUR+0.44 (+0.2%)17,658€180.62€191.00€178.20€182.36Close on Nov 20, 2026
B3:M1RN3459.00 BRL+1.60 (+2.8%)66,76658.2160.5057.0057.40Close on Nov 19, 2026
Frankfurt:0QF€174.26 EUR-7.36 (-4.1%)580€179.20€190.12€174.26€181.62Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MRNA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$195.00-1.79-0.9%$200.08$210.00$191.469,662,576
$196.79-10.01-4.8%$206.80$208.68$196.526,912,807
$206.80-8.47-3.9%$219.85$222.26$203.898,202,901
$215.27-8.10-3.6%$217.18$220.59$212.507,000,987
$223.37-7.98-3.4%$224.91$231.35$221.708,034,922
$231.35-17.34-7.0%$237.88$245.37$229.696,956,651
$248.69-2.14-0.9%$252.78$254.86$243.007,553,975
$250.83-18.17-6.8%$265.86$273.00$250.4911,129,237
$269.00+14.81+5.8%$258.99$280.80$253.5012,325,083
$254.19+12.73+5.3%$245.40$267.50$237.8616,285,337
$241.46-16.92-6.5%$258.01$260.67$237.6511,879,068
$258.38+29.94+13.1%$235.00$258.69$230.2114,722,489
$228.44+7.61+3.4%$222.02$235.46$220.239,490,033
$220.83-0.89-0.4%$224.16$230.52$217.668,414,057
$221.72-1.04-0.5%$221.11$227.53$217.228,988,811
$222.76+8.595+4.0%$216.26$224.96$215.3810,748,613
$214.17+6.195+3.0%$203.97$218.16$202.6211,992,751
$207.97+9.12+4.6%$193.00$208.87$179.5317,563,333
$198.85-1.25-0.6%$186.90$203.81$181.6517,051,717
$200.10-2.53-1.2%$196.69$206.97$183.0021,466,203
$202.63-43.18-17.6%$240.06$241.26$180.8049,812,057
$245.81+3.73+1.5%$242.20$254.48$239.5515,939,661
$242.08+15.19+6.7%$226.03$243.98$216.6516,796,983
$226.89+8.88+4.1%$217.27$236.77$216.0018,771,556
$218.01-18.49-7.8%$235.00$237.96$208.9221,368,200
$236.50+10.20+4.5%$225.48$242.29$217.0217,313,500
$226.30+10.05+4.6%$217.49$227.09$211.2416,625,400
$216.25+2.51+1.2%$207.63$218.48$204.7013,389,300
$213.74-11.26-5.0%$224.50$227.46$210.9112,873,900
$225.00+28.00+14.2%$199.00$225.00$197.1728,947,300
$197.00+0.52+0.3%$196.42$199.92$192.7137,400,000
$196.48+9.02+4.8%$183.65$197.69$182.5014,640,200
$187.46-15.75-7.8%$202.09$212.22$186.6418,794,800
$203.21+13.20+6.9%$191.41$205.77$185.9019,313,300
$190.01+1.07+0.6%$190.26$193.72$183.2810,289,500
$188.94-3.63-1.9%$186.61$201.00$186.0115,437,000
$192.57-10.89-5.4%$186.55$196.83$184.5820,649,500
$203.46+6.18+3.1%$197.78$208.90$190.0013,277,900
$197.28-1.60-0.8%$195.16$199.83$189.1013,359,600
$198.88+4.06+2.1%$195.35$202.67$192.5113,945,000
$194.82+12.71+7.0%$180.60$195.71$180.3916,605,500
$182.11-0.45-0.2%$183.41$192.31$181.3017,727,800
$182.56+9.62+5.6%$168.50$187.20$168.3024,033,900
$172.94+18.90+12.3%$161.05$176.86$159.0621,018,300
$154.04-4.03-2.5%$158.36$159.79$150.2620,229,600
$158.07+12.45+8.5%$152.50$161.96$149.5019,175,000
$145.62+1.85+1.3%$145.26$148.93$142.308,832,100
$143.77-2.92-2.0%$146.00$148.70$141.168,414,700
$146.69+2.72+1.9%$144.93$147.34$139.0210,963,000
$143.97+7.35+5.4%$137.91$149.73$135.0115,409,300
$136.62+1.01+0.7%$134.86$137.13$130.387,873,500
$135.61-4.72-3.4%$140.30$143.94$135.528,650,500
$140.33-5.22-3.6%$145.98$147.50$139.7010,308,600
$145.55-3.32-2.2%$153.62$154.69$141.5214,966,500
$148.87-1.94-1.3%$145.95$150.20$142.7813,290,400
$150.81-3.46-2.2%$151.40$156.42$146.5416,563,200
$154.27+13.93+9.9%$140.25$154.70$138.0925,831,700
$140.34+2.35+1.7%$134.10$144.20$133.8618,570,700
$137.99-4.78-3.3%$137.19$138.80$133.3325,820,600
$142.77-6.89-4.6%$144.18$148.59$138.5424,993,200
$149.66-9.17-5.8%$154.20$156.13$145.1022,009,500
$158.83+19.94+14.4%$143.50$161.37$141.2149,225,648
$138.89-6.24-4.3%$142.70$145.50$130.0031,587,240
$145.13+11.81+8.9%$133.11$159.47$132.4287,316,100
$133.32-41.06-23.5%$150.14$155.00$128.6199,499,900
Ticker
BVL:MRNAUS
Asset type
Stock
Exchange
BVL
Currency
PEN

What changed lately

Latest news

All Moderna, Inc. news

Moderna, Inc. on 6ix

News releases
58 in the last 12 months · 398 in all · newest Nov 12, 2026 · oldest 2021
Calls
26 calls with a replay · 26 with a transcript · latest Nov 6, 2026
Decks
65 decks · latest Nov 12, 2026

Where Moderna, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MRNA · Home listingNASDAQUnited StatesUSD
gettex:0QFgettexGermanyEUR
Milan:1MRNAMilanItalyEUR
Xetra:0QFXetraGermanyEUR
Tradegate:0QFTradegateGermanyEUR
BCBA:MRNABCBAArgentinaARS
LS Exchange:A2N9D9LS ExchangeGermanyEUR
BMV:MRNABMVMexicoMXN
B3:M1RN34B3BrazilBRL
BOATS:MRNABOATSUnited StatesUSD
EUROTLX:4MRNAEUROTLXItalyEUR
Lang & Schwarz:A2N9D9Lang & SchwarzGermanyEUR
LSIN:0A45LSINUnited KingdomUSD
BIVA:MRNABIVAMexicoMXN
BCBA:MRNADBCBAArgentinaUSD
Stuttgart:0QFStuttgartGermanyEUR
Frankfurt:0QFFrankfurtGermanyEUR
Aquis:0QFDAquisUnited KingdomEUR
SIX Swiss:MRNASIX SwissSwitzerlandCHF
Munich:0QFMunichGermanyEUR
VIE:MRNAViennaAustriaEUR
SIX Swiss:MRNA.USDSIX SwissSwitzerlandUSD
BCBA:MRNACBCBAArgentinaUSD
Dusseldorf:0QFDusseldorfGermanyEUR
BX Swiss:0QFBX SwissSwitzerlandCHF
Hamburg:0QFHamburgGermanyEUR
BSESOF:0QFBSESOFBulgariaEUR
BVL:MRNAUS · This pageBVLPeruPEN
Hanover:0QFHanoverGermanyEUR
Turquoise:MRNANTurquoiseUnited KingdomUSD
Aquis:0QFDAquisUnited KingdomEUR
BCBA:MRNA.CIBCBAArgentinaARS

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$77.91B USD
P/E
Loss
EV/sales
30.9×
EV/EBITDA
Negative EBITDA
Price/book
11.5×
Gross margin
28.0%
Operating margin
−116.0%
Net margin
−110.5%
Debt to equity
0.6×
Beta vs S&P 500
1.96

Forecasts

3 strong buy · 1 buy · 16 hold · 1 sell · 2 strong sell · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
155.50 USD · Analysts' mean
EPS, year to Dec 2026
-7.40 · 18 analysts
Revenue, year to Dec 2026
2.42B · 16 analysts

Team and board

Officers

OfficerRole
Stéphane BancelChief Executive Officer, Moderna
Lavina TalukdarSenior Vice President & Head of Investor Relations
Chris RidleyVP, Global Head of Communications
Noubar AfeyanCo-founder, Chairman, Moderna, Flagship Pioneering
Tracey FranklinChief People Officer

Board

DirectorRole
Noubar AfeyanCo-founder, Chairman, Moderna, Flagship Pioneering
Michael McDonnellDirector

Events

Calls

CallWhenStatus
Moderna (NASDAQ:MRNA) Q3 2026 Earnings CallFri, Nov 06, 2026 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q2 2026 Earnings CallFri, Jul 31, 2026 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q1 2026 Earnings CallFri, May 01, 2026 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q4 2025 Earnings CallFri, Feb 13, 2026 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q3 2025 Earnings CallThu, Nov 06, 2025 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q2 2025 Earnings CallFri, Aug 01, 2025 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q1 2025 Earnings CallThu, May 01, 2025 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q4 2024 Earnings CallFri, Feb 14, 2025 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q3 2024 Earnings CallThu, Nov 07, 2024 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q2 2024 Earnings CallThu, Aug 01, 2024 · 8:00 AM ETReplay
All 26 calls
CallWhenStatus
Moderna (NASDAQ:MRNA) Q1 2024 Earnings CallThu, May 02, 2024 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q4 2023 Earnings CallThu, Feb 22, 2024 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q3 2023 Earnings CallThu, Nov 02, 2023 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q2 2023 Earnings CallThu, Aug 03, 2023 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q1 2023 Earnings CallThu, May 04, 2023 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q4 2022 Earnings CallThu, Feb 23, 2023 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q3 2022 Earnings CallThu, Nov 03, 2022 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q2 2022 Earnings CallWed, Aug 03, 2022 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q1 2022 Earnings CallWed, May 04, 2022 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q4 2021 Earnings CallThu, Feb 24, 2022 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q2 2021 Earnings CallThu, Aug 05, 2021 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q1 2021 Earnings CallThu, May 06, 2021 · 8:00 AM ETReplay
Moderna (NASDAQ:MRNA) Q4 2020 Earnings CallThu, Feb 25, 2021Replay
Moderna (NASDAQ:MRNA) Q3 2020 Earnings CallThu, Oct 29, 2020Replay
Moderna (NASDAQ:MRNA) Q2 2020 Earnings CallWed, Aug 05, 2020Replay
Moderna (NASDAQ:MRNA) Q1 2020 Earnings CallThu, May 07, 2020Replay

Results days

QuarterResultsShare move
Q3 2026Nov 6, 2026 · Before open+5.3%
Q2 2026Jul 31, 2026 · Before open−5.3%
Q1 2026May 1, 2026 · Before open−1.2%
Q4 2025Feb 13, 2026 · Before open+5.3%
Q3 2025Nov 6, 2025 · Before open+3.3%
Q2 2025Aug 1, 2025 · Before open−6.6%
Q1 2025May 1, 2025 · Before open−5.3%
Q4 2024Feb 14, 2025 · Before open+3.4%
Q3 2024Nov 7, 2024 · Before open−3.0%
Q2 2024Aug 1, 2024 · Before open−21.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · Before open+12.7%
Q4 2023Feb 22, 2024 · Before open+13.5%
Q3 2023Nov 2, 2023 · Before open−6.5%
Q2 2023Aug 3, 2023 · Before open−0.2%
Q1 2023May 4, 2023 · Before open+3.2%
Q4 2022Feb 23, 2023 · Before open−6.7%
Q3 2022Nov 3, 2022 · Before open−0.8%
Q2 2022Aug 3, 2022 · Before open+16.0%
Q1 2022May 4, 2022 · Before open+5.8%
Q4 2021Feb 24, 2022 · Before open+15.1%

Open Events

Decks

DeckKindSlidesDate
Investor Day (November 2026)Investor day183 slidesNov 12, 2026
Q3 2026 Earnings PresentationEarnings32 slidesNov 6, 2026
Q2 2026 Earnings PresentationEarnings29 slidesJul 31, 2026
Q1 2026 Earnings PresentationEarnings25 slidesMay 1, 2026
Q4 2025 Earnings PresentationEarnings26 slidesFeb 13, 2026
44th Annual J.P. Morgan Healthcare Conference 2026Conference24 slidesJan 12, 2026
Q3 2025 Earnings PresentationEarnings26 slidesNov 6, 2025
Q2 2025 Earnings PresentationEarnings31 slidesAug 1, 2025
Q1 2025 Earnings PresentationEarnings29 slidesMay 1, 2025
35th Congress of the European Society of Clinical Microbiology & Infectious Diseases (ESCM (April 2025)Conference14 slidesApr 12, 2025
Show 50 decks
DeckKindSlidesDate
Technical Presentation (April 2025)Technical28 slidesApril 2025
Barclays Global Healthcare Conference 2025Conference4 slidesMar 11, 2025
Q4 2024 Earnings PresentationEarnings30 slidesFeb 14, 2025
43rd Annual J.P. Morgan Healthcare Conference 2025Conference25 slidesJan 13, 2025
Q3 2024 Earnings PresentationEarnings35 slidesNov 7, 2024
Investor Day (September 2024)Investor day141 slidesSep 12, 2024
Q2 2024 Earnings PresentationEarnings36 slidesAug 1, 2024
Q1 2024 Earnings PresentationEarnings34 slidesMay 2, 2024
Technical Presentation (April 2024)Technical17 slidesApr 29, 2024
Q4 2023 Earnings PresentationEarnings36 slidesFeb 22, 2024
8th ReSViNET Conference (RSVVW 2024)Conference32 slidesFeb 15, 2024
42nd Annual J.P. Morgan Healthcare Conference 2024Conference25 slidesJan 8, 2024
Investor Day (November 2023)Investor day60 slidesNov 8, 2023
Q3 2023 Earnings PresentationEarnings38 slidesNov 2, 2023
IDWeek 2023Conference14 slidesOct 14, 2023
Q2 2023 Earnings PresentationEarnings38 slidesAug 3, 2023
ASCO Investor Event (June 2023)Conference24 slidesJune 2023
Q1 2023 Earnings PresentationEarnings44 slidesMay 4, 2023
7th ReSViNET Conference (RSVVW 2023)Conference15 slidesFeb 23, 2023
Q4 2022 Earnings PresentationEarnings44 slidesFeb 23, 2023
41st Annual J.P. Morgan Healthcare Conference (January 2023)Conference32 slidesJan 9, 2023
ESG Presentation (November 2022)Sustainability106 slidesNov 10, 2022
Q3 2022 Earnings PresentationEarnings36 slidesNov 3, 2022
Investor Day (September 2022)Investor day179 slidesSep 8, 2022
Q2 2022 Earnings PresentationEarnings37 slidesAug 3, 2022
Technical Presentation (June 2022)Technical13 slidesJun 8, 2022
Investor Day (May 2022)Investor day136 slidesMay 17, 2022
Q1 2022 Earnings PresentationEarnings42 slidesMay 4, 2022
Q4 2021 Earnings PresentationEarnings48 slidesFeb 24, 2022
40th Annual J.P. Morgan Healthcare Conference (January 2022)Conference19 slidesJan 10, 2022
Q3 2021 Earnings PresentationEarnings51 slidesNov 4, 2021
Q2 2021 Earnings PresentationEarnings46 slidesAug 5, 2021
ESG Presentation (June 2021)Sustainability28 slidesJun 7, 2021
Q1 2021 Earnings PresentationEarnings43 slidesMay 6, 2021
Q4 2020 Earnings PresentationEarnings36 slidesFeb 25, 2021
39th Annual J.P. Morgan Healthcare Conference (January 2021)Conference37 slidesJan 11, 2021
Q3 2020 Earnings PresentationEarnings29 slidesOct 29, 2020
Corporate Update (October 2020)Corporate update7 slidesOct 8, 2020
Investor Day (September 2020)Investor day170 slidesSep 17, 2020
Q2 2020 Earnings PresentationEarnings34 slidesAug 5, 2020

This page holds 50 of 65 decks. Open Decks

Open Decks

Financings

RaiseDate
0.00% Convertible Senior Notes due 2032
Made bigger: US$2.6B
Use of proceeds: Pay about $285.0 million for capped call transactions and general corporate purposes, possibly including growing the oncology business and repaying debt
Aug 28, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.94B3.24B6.85B19.3B18.5B803.0M60.0M135.1M205.8M108.4M
Cost of revenue868.0M1.46B4.69B5.42B2.62B8.00M0020.5M15.1M
Gross profit1.08B1.74B2.15B13.5B15.1B266.6M48.0M-331.6M185.3M93.3M
Research and development3.13B4.54B4.84B3.29B1.99B1.37B496.0M454.1M410.5M274.7M
Selling, general and administrative1.02B1.03B1.34B1.01B567.0M188.3M109.6M94.3M64.7M57.5M
Operating income-3.07B-3.94B-4.24B9.42B13.3B-763.0M-546.0M-413.3M-269.4M-223.8M
Depreciation and amortization211.0M185.0M617.0M348.0M232.0M31.0M31.0M24.9M20.5M15.1M
EBITDA-2.86B-3.76B-3.62B9.77B13.5B-732.0M-515.0M-388.4M-248.8M-208.7M
Interest expense10.0M24.0M38.0M29.0M18.0M9.89M6.61M3.10M132.0K0
Income before tax-2.77B-3.61B-3.94B9.57B13.3B-744.0M-515.0M-384.4M-256.0M-215.2M
Income tax54.0M-46.0M772.0M1.21B1.08B3.00M-1.00M326.0K-80.0K1.04M
Net income-2.82B-3.56B-4.71B8.36B12.2B-747.0M-514.0M-384.7M-255.9M-216.2M
Earnings per share, basic-7.26-9.28-12.3321.2630.31-1.96-1.55-4.95-4.18-3.79
Earnings per share, diluted-7.26-9.28-12.3320.1228.29-1.96-1.55-4.95-4.18-3.79

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents2.60B1.93B2.91B3.21B6.85B2.62B236.0M658.4M134.9M50.1M
Short-term investments3.20B5.10B5.70B6.70B3.88B1.98B867.1M863.1M621.2M1.01B
Receivables184.0M358.0M892.0M1.39B3.17B1.39B5.37M11.7M11.9M18.0M
Inventory153.0M117.0M202.0M949.0M1.44B47.0M0-173.0M
Current assets6.54B8.10B10.3B13.4B16.1B6.30B1.13B1.56B783.2M1.09B
Property, plant and equipment2.14B1.38B387.1M287.9M212.0M139.0M81.2M
Goodwill52.0M52.0M52.0M03.50M3.56M
Total assets12.3B14.1B18.4B25.9B24.7B7.34B1.59B1.96B1.08B1.42B
Accounts payable317.0M405.0M520.0M487.0M302.0M18.0M7.09M31.2M20.7M28.2M
Current liabilities1.99B2.21B3.02B4.92B9.13B4.39B143.1M222.8M191.5M162.8M
Long-term debt590.0M015.7M12.5M
Total debt590.0M01.24B1.20B916.0M237.0M132.4M112.6M88.4M37.6M
Total liabilities3.69B3.24B4.57B6.74B10.5B4.78B414.6M431.9M459.2M575.3M
Shareholders' equity8.65B10.9B13.9B19.1B14.1B2.56B1.18B1.53B-551.4M-334.8M
Shares outstanding394.0M386.0M382.0M385.0M403.0M399.0M336.5M328.8M65.2M368.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-1.87B-3.00B-3.12B4.98B13.6B2.03B-459.0M-330.9M-331.5M66.7M
Capital spending-192.0M-1.05B-707.0M-400.0M-284.0M-68.0M-32.0M-105.8M-58.4M-33.1M
Free cash flow-2.06B-4.05B-3.83B4.58B13.3B1.96B-491.0M-436.6M-389.9M33.6M
Cash from investing1.95B1.95B4.21B-5.18B-8.52B-1.67B-15.0M-373.1M417.4M-648.6M
Cash from financing593.0M56.0M-1.38B-3.45B-873.0M2.03B52.0M1.23B168.0K472.9M
Dividends paid-270.0M-184.0M-124.0M-7.04M-1.48M-633.0K
Share buybacks-2.00M0-1.15B-3.33B-857.0M00-8.18M00
Change in cash668.0M-999.0M-289.0M-3.64B4.22B2.39B-422.0M522.9M86.0M-109.0M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
8-K · Current reportNov 16, 2026Material contractSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
8-K · Current reportNov 13, 2026Management or board changeSEC
4 · Change in ownershipNov 9, 2026Insider tradeSEC
10-Q · Quarterly reportNov 6, 2026Quarterly reportSEC
8-K · Current reportNov 6, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
144 · Notice of proposed saleOct 14, 2026Other filingsSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 5, 2026Insider tradeSEC
8-K · Current reportSep 30, 2026Management or board changeSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
144 · Notice of proposed saleSep 10, 2026Other filingsSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
8-K · Current reportSep 1, 2026Material contractSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 12, 2026Big-stake noticeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 5, 2026Other filingsSEC
10-Q · Quarterly reportJul 31, 2026Quarterly reportSEC
8-K · Current reportJul 31, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 24, 2026Big-stake noticeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 10, 2026Insider tradeSEC
8-K · Current reportJul 8, 2026Management or board changeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 30, 2026Insider tradeSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
144 · Notice of proposed saleMay 21, 2026Other filingsSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
8-K · Current reportMay 11, 2026Meeting outcomeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
4 · Change in ownershipMay 8, 2026Insider tradeSEC
144 · Notice of proposed saleMay 8, 2026Other filingsSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
10-Q · Quarterly reportMay 1, 2026Quarterly reportSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
8-K · Current reportMay 1, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 30, 2026Big-stake noticeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialMar 16, 2026Meeting noticeSEC
DEF 14A · Proxy statementMar 16, 2026Meeting noticeSEC
ARS · Annual report to shareholdersMar 16, 2026Annual reportSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
8-K · Current reportMar 4, 2026Material contractSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
S-8 · Registration statement for employee plansFeb 20, 2026Offer documentSEC
10-K · Annual reportFeb 20, 2026Annual reportSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
8-K · Current reportFeb 13, 2026ResultsSEC
8-K · Current reportFeb 10, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
8-K · Current reportJan 5, 2026Current reportSEC
SC TO-I/ADec 16, 2025Acquisition or disposalSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
144 · Notice of proposed saleDec 11, 2025Other filingsSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
144 · Notice of proposed saleDec 9, 2025Other filingsSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 2, 2025Insider tradeSEC
4 · Change in ownershipDec 2, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
8-K · Current reportNov 24, 2025Material contractSEC
8-K · Current reportNov 20, 2025Current reportSEC
SC TO-I/ANov 18, 2025Acquisition or disposalSEC
8-K · Current reportNov 13, 2025Meeting outcomeSEC
SC TO-INov 13, 2025Acquisition or disposalSEC
SC TO-CNov 12, 2025Other filingsSEC
SC TO-CNov 6, 2025Other filingsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
SC TO-COct 21, 2025Other filingsSEC
DEFA14A · Additional proxy materialOct 20, 2025Meeting noticeSEC
DEF 14A · Proxy statementOct 15, 2025Meeting noticeSEC
SC TO-COct 10, 2025Other filingsSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
SC TO-COct 3, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementOct 3, 2025Meeting noticeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
4 · Change in ownershipAug 6, 2025Insider tradeSEC
10-Q · Quarterly reportAug 1, 2025Quarterly reportSEC
8-K · Current reportAug 1, 2025ResultsSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
144 · Notice of proposed saleJun 11, 2025Other filingsSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2025Big-stake noticeSEC
8-K · Current reportMay 5, 2025Meeting outcomeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
4 · Change in ownershipMay 1, 2025Insider tradeSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 30, 2025Big-stake noticeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
DEFA14A · Additional proxy materialMar 11, 2025Meeting noticeSEC
DEF 14A · Proxy statementMar 11, 2025Meeting noticeSEC
ARS · Annual report to shareholdersMar 11, 2025Annual reportSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 21, 2025Offer documentSEC
10-K · Annual reportFeb 21, 2025Annual reportSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
8-K · Current reportFeb 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025ResultsSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
144 · Notice of proposed saleDec 9, 2024Other filingsSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC

This page holds 200 of 1,003 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Moderna, Inc.’s releases · as of Oct 30, 2026

Common shares
404,620,975
Fully diluted
404,620,975

Fully diluted

LineSharesAs of
Common shares404,620,975Oct 30, 2026

Share count over time

CountShares
Oct 30, 2026404,620,975

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity59M14.6%US$11.4BSep 30, 2026
Vanguard43.1M10.6%US$8.29BSep 30, 2026
BlackRock27.8M6.9%US$5.35BSep 30, 2026
Capital Group22.6M5.6%US$4.36BSep 30, 2026
State Street15.5M3.8%US$2.98BSep 30, 2026
Baillie Gifford & Co11.4M2.8%US$2.2BSep 30, 2026
Geode Capital10.2M2.5%US$1.97BSep 30, 2026
T. Rowe Price7.62M1.9%US$1.47BSep 30, 2026
Theleme Partners LLP6.66M1.6%US$1.28BSep 30, 2026
UBS6.53M1.6%US$1.26BSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Morgan Stanley6.02M1.5%US$1.16BSep 30, 2026
Goldman Sachs5.94M1.5%US$1.14BSep 30, 2026
Flagship Pioneering, LLC4.63M1.1%US$892MSep 30, 2026
BNP Paribas4.03M1.00%US$776MSep 30, 2026
Millennium3.89M0.96%US$750MSep 30, 2026
Wellington3.72M0.92%US$716MSep 30, 2026
Schwab3.22M0.79%US$619MSep 30, 2026
Northern Trust3.01M0.74%US$579MSep 30, 2026
Qube Research & Technologies Ltd2.92M0.72%US$563MSep 30, 2026
Susquehanna2.89M0.72%US$557MSep 30, 2026
Invesco2.62M0.65%US$505MSep 30, 2026
JPMorgan2.56M0.63%US$526MSep 30, 2026
Merck & Co., Inc.2.31M0.57%US$444MSep 30, 2026
Citigroup Inc2.27M0.56%US$436MSep 30, 2026
Banque Pictet & Cie SA2.15M0.53%US$414MSep 30, 2026
Dimensional2.09M0.52%US$404MSep 30, 2026
Hrt Financial LP1.82M0.45%US$351MSep 30, 2026
BNY1.69M0.42%US$325MSep 30, 2026
Bamco Inc1.39M0.34%US$268MSep 30, 2026
Douglas Lane & Associates, LLC1.16M0.29%US$224MSep 30, 2026
Allianz1.11M0.27%US$214MSep 30, 2026
Beau Ventures, LLc1M0.25%US$193MSep 30, 2026
Bank of America978K0.24%US$188MSep 30, 2026
Nuveen828K0.20%US$160MSep 30, 2026
Amundi823K0.20%US$159MSep 30, 2026
Lingotto Investment Management LLP749K0.19%US$144MSep 30, 2026
Step Capital Management Pte. Ltd.705K0.17%US$136MSep 30, 2026
Legal & General703K0.17%US$135MSep 30, 2026
Swiss National Bank689K0.17%US$133MSep 30, 2026
Barclays656K0.16%US$126MSep 30, 2026
MUFG588K0.15%US$113MSep 30, 2026
Nomura552K0.14%US$106MSep 30, 2026
Rhumbline Advisers550K0.14%US$106MSep 30, 2026
Ofi Invest Asset Management546K0.14%US$92.6MSep 30, 2026
HSBC546K0.14%US$105MSep 30, 2026
Russell Investments Group, Ltd.532K0.13%US$103MSep 30, 2026
TD516K0.13%US$103MSep 30, 2026
DWS516K0.13%US$99.4MSep 30, 2026
LMR Partners LLP506K0.13%US$97.5MSep 30, 2026
Holocene Advisors, LP506K0.13%US$97.4MSep 30, 2026

This page holds 50 of 1,027 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Growth Fund of America14.5M3.6%US$684MMay 31, 2026
Vanguard Total Stock Market Index Fund11.3M2.8%US$794MJun 30, 2026
Vanguard 500 Index Fund9.15M2.3%US$641MJun 30, 2026
Vanguard Small-Cap Index Fund8.19M2.0%US$574MJun 30, 2026
Fidelity Growth Company Fund6.21M1.5%US$293MMay 31, 2026
Fidelity OTC Portfolio5.31M1.3%US$291MJul 31, 2026
Vanguard Small-Cap Value Index Fund5.19M1.3%US$363MJun 30, 2026
iShares Core S&P 500 ETF4.86M1.2%US$340MJun 30, 2026
Growth Fund4.62M1.1%US$324MJun 30, 2026
Vanguard International Growth Fund4.58M1.1%US$216MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity 500 Index Fund4.45M1.1%US$210MMay 31, 2026
Fidelity Contrafund4.34M1.1%US$304MJun 30, 2026
Invesco S&P 500 Equal Weight ETF4.05M1.0%US$222MJul 31, 2026
iShares Biotechnology ETF2.57M0.64%US$180MJun 30, 2026
Vanguard U.S. Growth Fund2.55M0.63%US$120MMay 31, 2026
State Street(R) Health Care Select Sector SPDR(R) ETF2.49M0.62%US$175MJun 30, 2026
Vanguard Health Care Fund2.35M0.58%US$129MJul 31, 2026
Fidelity Puritan Fund2.28M0.56%US$108MMay 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.16M0.54%US$152MJun 30, 2026
Capital Group Growth ETF2.02M0.50%US$95.3MMay 31, 2026
Baron Partners Fund1.99M0.49%US$139MJun 30, 2026
Vanguard Institutional Index Fund1.92M0.47%US$134MJun 30, 2026
Fidelity Growth Company K6 Fund1.72M0.43%US$81.3MMay 31, 2026
iShares Russell Mid-Cap ETF1.49M0.37%US$105MJun 30, 2026
Select Health Care Portfolio1.45M0.36%US$68.4MMay 31, 2026
Select Biotechnology Portfolio1.43M0.35%US$67.6MMay 31, 2026
Fidelity Series Growth Company Fund1.42M0.35%US$66.9MMay 31, 2026
T. Rowe Price Health Sciences Fund, Inc.1.41M0.35%US$98.9MJun 30, 2026
Fidelity Mid Cap Index Fund1.38M0.34%US$75.6MJul 31, 2026
Fidelity Advisor Equity Growth Fund1.32M0.33%US$62.3MMay 31, 2026
VIP Growth Portfolio1.02M0.25%US$71.5MJun 30, 2026
Fidelity Blue Chip Growth Fund954K0.24%US$52.3MJul 31, 2026
Fidelity Contrafund K6945K0.23%US$66.2MJun 30, 2026
Schwab U.S. Mid-Cap ETF940K0.23%US$44.4MMay 31, 2026
Vanguard Health Care Index Fund911K0.23%US$43MMay 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund843K0.21%US$39.8MMay 31, 2026
State Street(R) SPDR(R) Portfolio S&P 500(R) ETF839K0.21%US$58.8MJun 30, 2026
Schwab Fundamental U.S. Large Company ETF819K0.20%US$38.6MMay 31, 2026
iShares Russell 1000 Value ETF811K0.20%US$56.8MJun 30, 2026
Schwab S&P 500 Index Fund791K0.20%US$43.4MJul 31, 2026
Schwab U.S. Large-Cap Growth ETF743K0.18%US$35.1MMay 31, 2026
Fidelity Total Market Index Fund659K0.16%US$31.1MMay 31, 2026
Federated Hermes MDT Market Neutral Fund659K0.16%US$46.1MJun 30, 2026
Fidelity Advisor Biotechnology Fund641K0.16%US$35.1MJul 31, 2026
Fidelity Advisor Health Care Fund585K0.14%US$32.1MJul 31, 2026
iShares S&P 500 Value ETF581K0.14%US$40.7MJun 30, 2026
Fidelity Mid-Cap Stock Fund572K0.14%US$31.3MJul 31, 2026
Fidelity Balanced Fund564K0.14%US$26.6MMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio561K0.14%US$26.5MMay 29, 2026
iShares Russell Mid-Cap Value ETF560K0.14%US$39.2MJun 30, 2026

This page holds 50 of 591 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Hoge Stephen
Officer: President
Sale33,976USD 211.45US$7.18MNov 17, 2026
Hoge Stephen
Officer: President
Sale5,082USD 212.57US$1.08MNov 17, 2026
Hoge Stephen
Officer: President
Sale157USD 214.19US$33,628Nov 17, 2026
Hoge Stephen
Officer: President
Sale39,160USD 219.66US$8.6MNov 16, 2026
Hoge Stephen
Officer: President
Sale39,145USD 220.72US$8.64MOct 15, 2026
Hoge Stephen
Officer: President
Sale38,774USD 213.47US$8.28MOct 14, 2026
Hoge Stephen
Officer: President
Sale450USD 214.15US$96,368Oct 14, 2026
Hoge Stephen
Officer: President
Sale40,281USD 146.07US$5.88MSep 15, 2026
Hoge Stephen
Officer: President
Sale40,294USD 144.13US$5.81MSep 14, 2026
Mock James M
Officer: Chief Financial Officer
Sale19,836USD 134.49US$2.67MSep 10, 2026
All 22 trades
TradeTradeSharesPriceValueDate
Mock James M
Officer: Chief Financial Officer
Sale15,000USD 134.49US$2.02MSep 10, 2026
Klinger Shannon Thyme
Officer: Chief Legal Officer
Sale3,471USD 139.95US$486KSep 1, 2026
Bancel Stephane
Director, Officer: Chief Executive Officer
Sale147,473USD 56.21US$8.29MAug 5, 2026
Bancel Stephane
Director, Officer: Chief Executive Officer
Sale124,838USD 56.96US$7.11MAug 5, 2026
Bancel Stephane
Director, Officer: Chief Executive Officer
Sale39,891USD 58.12US$2.32MAug 5, 2026
Bancel Stephane
Director, Officer: Chief Executive Officer
Sale187,044USD 58.79US$11MAug 5, 2026
Hoge Stephen
Officer: President
Sale53,336USD 67.60US$3.61MJul 15, 2026
Hoge Stephen
Officer: President
Sale53,336USD 51.37US$2.74MJun 15, 2026
Klinger Shannon Thyme
Officer: Chief Legal Officer
Sale3,471USD 50.00US$174KJun 4, 2026
Afeyan Noubar
Director
Sale9,263USD 46.84US$434KMay 21, 2026
Hoge Stephen
Officer: President
Sale53,336USD 48.40US$2.58MMay 15, 2026
Hussain Abbas
Director
Sale5,682USD 46.63US$265KMay 1, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC14.80%58.9MSep 30, 2026Schedule 13G
Vanguard Capital Management LLC6.53%25.9MMar 31, 2026Schedule 13G
Capital World Investors5.60%22.3MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Noubar Afeyan
Other companies: Generate Biomedicines, Inc. (Chair of the Board · Since at least Feb 26, 2026); Foghorn Therapeutics Inc. (Director · Since at least Jan 13, 2026); BG Medicine Inc (Director · Since at least Feb 3, 2011); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Mar 4, 2019 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 21, 2016 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past); Agenus Inc. (Director · Jan 13, 2005 – Jun 7, 2007 · Past)
Director · Since at least Dec 7, 2018
François Nader
Other companies: Tectonic Therapeutic, Inc. (Chair, Board of Directors · Since at least Feb 23, 2026); Tourmaline Bio Inc. (Director · May 6, 2021 – Jun 13, 2023 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Alexion Pharmaceuticals Inc (Director · Nov 15, 2017 – Jul 21, 2021 · Past); Baxalta Inc (Director · Jul 27, 2015 – Jun 3, 2016 · Past); Acceleron Pharma Inc (Director · Dec 11, 2014 – Nov 19, 2021 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 20, 2015 · Past); NPS Pharmaceuticals Inc (President, CEO and Director, Director · Apr 8, 2013 – Feb 21, 2015 · Past)
Director · Since at least Dec 10, 2019
Paul Sagan
Other companies: Okta, Inc. (Director · Since at least Dec 19, 2025); Catalyst Partners Acquisition Corp (President, Director · May 17, 2021 – Feb 7, 2023 · Past); VMware Inc (Director · Apr 7, 2014 – Nov 22, 2023 · Past); iRobot Corporation (Director · Feb 1, 2010 – Jun 5, 2015 · Past); EMC Corporation (Director · Dec 19, 2007 – Sep 6, 2016 · Past); Dow Jones & Co Inc (Director · Apr 18, 2007 – Dec 13, 2007 · Past); Digitas Inc (Director · Jul 25, 2006 – Jan 25, 2007 · Past); Akamai Technologies, Inc. (Director · Oct 4, 2005 – May 15, 2019 · Past)
Director · Dec 7, 2018 – Apr 30, 2025 · Past
David Meline
Other companies: Lonza Group AG (Independent Member of the Board of Directors · Since at least May 8, 2026); Eikon Therapeutics, Inc. (Director · Since at least Feb 4, 2026); HP Inc. (Director · Since at least Nov 1, 2023); Pacific Biosciences of California, Inc. (Director · Oct 13, 2023 – Jun 18, 2024 · Past); Amgen Inc. (EVP & CFO · Jul 21, 2014 – Nov 25, 2019 · Past); TRW Automotive Holdings Corp (Director · Feb 12, 2014 – May 13, 2014 · Past); 3M Company (Former Sr. VP & CFO · Sep 2, 2008 – Apr 30, 2014 · Past)
Chief Financial Officer · Jun 8, 2020 – Aug 9, 2022 · Past
Robert Langer
Other companies: Seer, Inc. (Director · Since at least Dec 3, 2020); Lyra Therapeutics, Inc. (David H. Koch Institute Professor, Massachusetts Institute of Technology · Since at least Apr 30, 2020); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – Oct 14, 2019 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 12, 2018 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Jun 21, 2016 · Past); Ocata Therapeutics Inc (Director · Oct 4, 2011 – Feb 10, 2016 · Past)
Director · Dec 7, 2018 – May 6, 2024 · Past
Michael McDonnell
Other companies: Baxter International Inc. (Director · Since at least Feb 13, 2026); Merit Medical Systems, Inc. (Audit Committee · Since at least May 19, 2022); Biogen Inc. (EVP, Chief Financial Officer · Aug 15, 2020 – Feb 10, 2025 · Past); Frontier Communications Corporation (Director · Dec 12, 2018 – Apr 1, 2019 · Past); IQVIA Holdings, Inc. (EVP and CFO · Dec 16, 2015 – Jul 5, 2020 · Past)
Director · Since at least Jul 8, 2026
Sandra J. Horning
Other companies: Revolution Medicines, Inc. (Director · Since at least Nov 9, 2023); Olema Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2020); Gilead Sciences, Inc. (Director · Since at least Jan 28, 2020); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Foundation Medicine Inc (Director · Apr 7, 2015 – Apr 7, 2015 · Past)
Director · Since at least Apr 29, 2020
John Mendlein
Other companies: Fate Therapeutics, Inc. (Director · Since at least Sep 30, 2013); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 20, 2024 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Jun 15, 2017 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 8, 2019 · Past)
See Remarks · Dec 7, 2018 – Dec 7, 2018 · Past
Jorge M Gomez
Other companies: Pear Therapeutics Inc (Director · Dec 3, 2021 – Dec 3, 2021 · Past); Dentsply Sirona Inc. (EVP, CFO · Aug 26, 2019 – Apr 8, 2022 · Past); Xylem Inc. (Director · Mar 27, 2019 – May 11, 2022 · Past); Cardinal Health, Inc. (Chief Financial Officer · Jan 1, 2018 – Nov 8, 2018 · Past)
See Remarks · May 9, 2022 – May 9, 2022 · Past
Lorence H Kim
Other companies: Cencora, Inc. (Director · Since at least Oct 1, 2022); Revolution Medicines, Inc. (Director · Since at least Jul 12, 2022); Cowen Group Inc (Director · Feb 15, 2022 – Mar 1, 2023 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 13, 2019 · Past)
Chief Financial Officer · Dec 7, 2018 – Jun 2, 2020 · Past
All 32 people
PersonSeat
Stéphane Bancel
Other companies: Generate Biomedicines, Inc. (Director · Since at least Feb 26, 2026); BG Medicine Inc (Executive Chairman of the Board · Since at least Feb 3, 2011); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Sep 15, 2016 · Past); Targanta Therapeutics Corp (Director · Aug 25, 2008 – Aug 25, 2008 · Past)
Chief Executive Officer, Moderna · Since at least Dec 7, 2018
Corinne Le Goff
Other companies: Viatris Inc. (Chief Commercial Officer · Since at least Apr 15, 2024); Imunon, Inc. (President and CEO, Director · Jul 18, 2022 – Mar 17, 2023 · Past); Longboard Pharmaceuticals Inc (Director · Mar 11, 2021 – Dec 2, 2024 · Past)
Chief Commercial Officer · Jan 19, 2021 – Feb 1, 2021 · Past
Elizabeth E Tallett
Other companies: Elevance Health, Inc. (Director · May 19, 2016 – May 15, 2024 · Past); Meredith Corporation (Director · Nov 11, 2015 – Nov 9, 2021 · Past); Principal Financial Group Inc (Director · Aug 14, 2015 – Jun 25, 2021 · Past)
Director · Since at least Jul 1, 2020
Elizabeth Nabel
Other companies: Lyell Immunopharma, Inc. (Director · Since at least Jun 16, 2021); Medtronic plc. (Director · Since at least Sep 16, 2014); Accolade, Inc. (Director · Jun 2, 2021 – Apr 8, 2025 · Past)
Director · Since at least Dec 7, 2018
Juan Andres
Other companies: Lonza Group AG (Independent Member of the Board of Directors · Since at least May 8, 2026); Evelo Biosciences, Inc. (Director · Dec 4, 2019 – Jun 8, 2023 · Past); Avantor, Inc. (Director · Sep 20, 2019 – May 8, 2025 · Past)
See remarks · Dec 7, 2018 – Dec 28, 2022 · Past
Moncef Slaoui
Other companies: Arcturus Therapeutics Holdings Inc. (Director · Since at least Jun 19, 2024); Vaxcyte, Inc. (Director · Since at least Jun 11, 2020); Intellia Therapeutics, Inc. (Director · Jul 24, 2017 – Jul 25, 2017 · Past)
Director · Dec 7, 2018 – Apr 29, 2020 · Past
Tal Zaks
Other companies: Teva Pharmaceutical Industries Limited (Independent Director · Since at least Oct 1, 2021); Adaptimmune Therapeutics PLC (Director · Nov 14, 2016 – Jul 1, 2022 · Past)
Chief Medical Officer · Dec 7, 2018 – Jun 30, 2021 · Past
Abbas Hussain
Other companies: Mallinckrodt Inc (Director · Since at least Feb 2, 2024)
Director · Since at least Oct 2, 2024
David M. Rubenstein
Other companies: The Carlyle Group Inc. (Partner, Co-Founder and Co-Chairman · Since at least May 3, 2012)
Director · Since at least Aug 5, 2024
Israel Ruiz
Other companies: Fortive Corporation (Director · Jun 13, 2016 – Jun 4, 2019 · Past)
Director · Dec 7, 2018 – Jun 27, 2019 · Past
Jennifer Ling Lee
Other companies: Standard BioTools Inc. (See Remarks · May 18, 2016 – Feb 20, 2018 · Past)
Chief Accounting Officer · Dec 7, 2018 – Mar 9, 2020 · Past
Lori M Henderson
Other companies: Albany Molecular Research Inc (SVP, Secretary & Gen Counsel · Nov 2, 2016 – Aug 31, 2017 · Past)
General Counsel and Secretary · Dec 7, 2018 – May 27, 2021 · Past
Paul Burton
Other companies: Amgen Inc. (Senior Vice President and Chief Medical Officer · Since at least Oct 27, 2026)
Chief Medical Officer · Jul 5, 2021 – Nov 4, 2022 · Past
Shannon Thyme Klinger
Other companies: Rafael Holdings, Inc. (Director · Jun 14, 2021 – Jan 5, 2022 · Past)
Chief Legal Officer · Since at least Jun 1, 2021
Soria Ester Banque
Other companies: Zoetis Inc. (Executive Vice President · Jul 10, 2023 – Oct 4, 2024 · Past)
Chief Commercial Officer · Since at least Jun 15, 2026
Stephen Berenson
Other companies: Seres Therapeutics, Inc. (Director · Since at least Jun 22, 2022)
Director · Apr 28, 2022 – May 3, 2024 · Past
Stephen Hoge
Other companies: Axcella Health Inc (Director · May 8, 2019 – May 20, 2021 · Past)
President · Since at least Dec 7, 2018
Arpa GarayChief Commercial Officer · Dec 5, 2023 – Dec 5, 2023 · Past
Chris RidleyVP, Global Head of Communications · Since at least Oct 23, 2026
James M MockChief Financial Officer · Since at least Apr 4, 2025
Lavina TalukdarSenior Vice President & Head of Investor Relations · Since at least Oct 23, 2026
Tracey FranklinChief People Officer · Since at least Oct 23, 2026

Open People

Log in to ask 6ix AI your own questions about Moderna, Inc.